annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
Brd. 40G Phase II study of cixutumumab (IMC-A12) plus depot octreotide for patients
with metastatic carcinoid or islet cell carcinoma. (Abstract #TPS220)
L. B. Anthony, P. J. Loehrer, S. Leong, M. H. Shah, H. Safran, N. N. Senzer, N. J.
Zojwalla, H. Youssoufian
Brd. 40H A multicenter randomized phase II study of UFT/leucovorin and radiotherapy
(RT) with or without cetuximab following induction gemcitabine plus
capecitabine (GEM-CAP) in locally advanced pancreatic cancer (LAPC).
(Abstract #TPS221)
I. Y. Chong, A. F. Okines, D. M. Tait, M. Hawkins, D. Cunningham, C. Saffery, K.
Thomas, I. Chau
Brd. 41A A Cancer Research UK multicenter randomized phase II study of induction
chemotherapy followed by gemcitabine- or capecitabine-based
chemoradiotherapy for locally advanced nonmetastatic pancreatic cancer.
(Abstract #TPS222)
S. Mukherjee, C. Hurt, G. Griffiths, T. Crosby, J. Staffurth, S. Bridges, J. A.
Bridgewater, A. Mcdonald, S. Falk, T. S. Maughan, scaloptmg
Brd. 41B SWOG S0727: A randomized phase II trial of combination gemcitabine plus
erlotinib plus IMC-A12 (cixutumumab) versus gemcitabine plus erlotinib as
first-line treatment in patients (pts) with metastatic pancreatic cancer.
(Abstract #TPS223)
P. A. Philip, B. H. Goldman, R. K. Ramanathan, H. Lenz, A. M. Lowy, R. P.
Whitehead, S. Iqbal, V. M. Chung, J. K. Benedetti, C. D. Blanke
Brd. 41C APRICoT-P: A phase II randomized placebo controlled study of apricoxib, a
potent COX-2 inhibitor in combination with erlotinib and gemcitabine in
pancreatic cancer patients. (Abstract #TPS224)
G. P. Keogh, R. M. Langdon, P. J. Stella, R. Manges, C. H. Chay, E. Looper, S. L.
Zaknoen
Brd. 41D CONKO-008: Oxaliplatin (O)/folinic acid (FA)/5-fluorouracil (5-FU) (24 h) in
combination with lapatinib as a second-line therapy in pancreatic cancer
after gemcitabine failure: A phase I/II trial. (Abstract #TPS225)
J. Stieler, U. Pelzer, M. Sinn, B. Dörken, H. Oettle, H. Riess
Brd. 41E A randomized, placebo-controlled, multicenter phase II adjuvant trial of the
efficacy, immunogenicity, and safety of GI-4000 plus gemcitabine versus
gemcitabine alone in patients with resected pancreatic cancer with activating
ras mutations. (Abstract #TPS226)
S. H. Whiting, P. Muscarella, A. Rosemurgy, W. E. Fisher, D. A. Richards, F. E.
Harrell Jr., J. Ferraro, S. Speyer, A. Cohn
Genitourinary Cancer
Brd. 41F Novel early stopping rule uses early progression rather than lack of
response as rapid assessment for futility. (Abstract #TPS227)
Y. Wong, S. Litwin, D. J. Vaughn, E. R. Plimack, S. M. Cohen, H. Tuttle, G. R.
Hudes
Brd. 41G A randomized phase II study of a novel antigen-presenting cell-targeted
hCG-� vaccine (the CDX-1307 regimen) in muscle-invasive bladder cancer.
(Abstract #TPS228)
D. A. Bradley, M. Morse, T. Keler, J. A. Green, T. A. Davis, B. A. Inman
Brd. 41H Phase II study of everolimus (RAD001) in metastatic transitional cell
carcinoma (TCC) of the urothelium. (Abstract #TPS229)
M. I. Milowsky, A. Trout, A. M. Regazzi, I. Garcia-Grossman, A. Flaherty, S. Tickoo,
H. Al-Ahmadie, D. F. Bajorin
Brd. 42A Pilot study of external hyperthermia and intravesical mitomycin-C to treat
recurrent bladder cancer after failed standard therapy. (Abstract #TPS230)
Z. Vujaskovic, O. I. Craciunescu, P. Stauffer, M. Carroll, L. Lan, M. Dewhirst, B. A.
Inman
324